Cns Financial Statements From 2010 to 2024

CNSP Stock  USD 0.38  0.01  2.70%   
Cns Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Cns Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cns Pharmaceuticals financial statements helps investors assess Cns Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cns Pharmaceuticals' valuation are summarized below:
Market Capitalization
3.2 M
Earnings Share
(7.60)
There are currently one hundred three fundamental signals for Cns Pharmaceuticals that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate Cns Pharmaceuticals' prevailing fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction.
Check Cns Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cns main balance sheet or income statement drivers, such as Interest Income of 34.9 K, Interest Expense of 14.1 K or Selling General Administrative of 3.8 M, as well as many exotic indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or Price Book Value Ratio of 0.38. Cns financial statements analysis is a perfect complement when working with Cns Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Cns Pharmaceuticals Technical models . Check out the analysis of Cns Pharmaceuticals Correlation against competitors.
To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.

Cns Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets8.5 M15 M4.7 M
Slightly volatile
Short and Long Term Debt Total368.7 K471.5 K253.9 K
Slightly volatile
Other Current LiabilitiesM952.6 K309.5 K
Slightly volatile
Total Current Liabilities5.9 M5.7 M1.6 M
Slightly volatile
Accounts Payable4.4 M4.2 MM
Slightly volatile
Cash6.7 M11.6 M3.7 M
Slightly volatile
Cash And Short Term Investments6.7 M11.6 M3.7 M
Slightly volatile
Common Stock Total Equity17.4 K27.4 K15.2 K
Slightly volatile
Common Stock Shares Outstanding1.2 M1.2 M8.8 M
Slightly volatile
Liabilities And Stockholders Equity8.5 M15 M4.7 M
Slightly volatile
Non Current Liabilities Total4.9 M4.7 M1.3 M
Slightly volatile
Capital Surpluse42.1 M40.1 M14.3 M
Slightly volatile
Other Current AssetsM2.9 M896.9 K
Slightly volatile
Other Stockholder Equity71.1 M67.7 M20.1 M
Slightly volatile
Total Liabilities5.9 M5.7 M1.6 M
Slightly volatile
Short and Long Term Debt368.7 K471.5 K253.9 K
Slightly volatile
Total Current Assets8.1 M14.4 M4.5 M
Slightly volatile
Short Term Debt368.7 K471.5 K253.9 K
Slightly volatile
Common Stock1.8 K1.9 K11.2 K
Very volatile
Current Deferred Revenue18.9 K21.2 K23.1 K
Slightly volatile
Other Assets1.5 M1.5 M468.8 K
Slightly volatile
Deferred Long Term Liabilities279.9 K384.3 K190.5 K
Slightly volatile
Capital Stock1.4 K1.5 K12.5 K
Pretty Stable
Property Plant And Equipment Net4.8 K5.1 K15.8 K
Slightly volatile
Property Plant And Equipment Gross22.9 K26.9 K20.1 K
Slightly volatile
Property Plant Equipment15.4 K14.5 K17.8 K
Slightly volatile
Good Will267.3 K300.7 K327.5 K
Slightly volatile

Cns Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income34.9 K50.9 K22.9 K
Slightly volatile
Selling General Administrative3.8 M5.8 M1.9 M
Slightly volatile
Research Development13.4 M12.8 M3.5 M
Slightly volatile
Total Operating Expenses9.8 M18.6 M5.1 M
Slightly volatile
Other Operating Expenses9.6 M17.6 M5.2 M
Slightly volatile
Income Tax ExpenseK6.3 K33 K
Slightly volatile
Cost Of Revenue10.4 K13.5 K5.3 K
Slightly volatile
Reconciled Depreciation9.6 K5.6 K4.7 K
Slightly volatile

Cns Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock17.2 M16.4 M5.8 M
Slightly volatile
Depreciation7.4 K5.6 K4.6 K
Slightly volatile
Capital Expenditures1.7 K1.7 K15.5 K
Slightly volatile
Total Cash From Financing Activities8.5 M7.8 M4.4 M
Slightly volatile
End Period Cash Flow864.1 K909.5 K2.6 M
Slightly volatile
Change To Netincome1.7 M1.6 M1.1 M
Slightly volatile
Change To Liabilities460.8 K663 K317.4 K
Slightly volatile
Stock Based Compensation1.1 M1.1 M522 K
Slightly volatile
Begin Period Cash Flow6.2 MM2.7 M
Slightly volatile
Other Non Cash Items288.3 K303.5 KM
Slightly volatile
Issuance Of Capital Stock9.7 M7.5 M4.4 M
Slightly volatile
Cash And Cash Equivalents Changes5.4 M6.1 M6.7 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Days Of Payables Outstanding108 K102.9 K62.6 K
Slightly volatile
Ebt Per Ebit1.091.155.4466
Slightly volatile
Payables Turnover0.00350.00370.0065
Pretty Stable
Cash Per Share8.86.655.0392
Slightly volatile
Quick Ratio2.232.352.9237
Pretty Stable
Dividend Paid And Capex Coverage Ratio2.3 K2.1 K755
Slightly volatile
Net Income Per E B T1.11.151.024
Slightly volatile
Cash Ratio2.232.352.9237
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.11.151.0207
Slightly volatile
Current Ratio2.182.33.3604
Pretty Stable
Capital Expenditure Coverage Ratio2.3 K2.1 K755
Slightly volatile
Debt Ratio0.03430.03610.4449
Slightly volatile

Cns Fundamental Market Drivers

Cash And Short Term Investments10.1 M

Cns Upcoming Events

1st of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Cns Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cns Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Cns Pharmaceuticals investors use historical funamental indicators, such as Cns Pharmaceuticals's revenue or net income, to determine how well the company is positioned to perform in the future. Although Cns Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Cns Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cns Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cns Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cns Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2024
Current Deferred Revenue21.2 K18.9 K
Total Revenue 0.00  0.00 
Cost Of Revenue13.5 K10.4 K
Ebit Per Revenue 0.00  0.00 

Pair Trading with Cns Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cns Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cns Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cns Stock

  0.74MBRX Moleculin Biotech Upward RallyPairCorr
  0.67MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr

Moving against Cns Stock

  0.87MRK Merck Company Fiscal Quarter End 31st of March 2024 PairCorr
  0.84DNTH Dianthus Therapeutics Symbol ChangePairCorr
  0.83MGNX MacroGenics Financial Report 14th of May 2024 PairCorr
  0.67URGN UroGen Pharma Financial Report 9th of May 2024 PairCorr
  0.65EQ Equillium Financial Report 9th of May 2024 PairCorr
The ability to find closely correlated positions to Cns Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cns Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cns Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cns Pharmaceuticals to buy it.
The correlation of Cns Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cns Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cns Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cns Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Cns Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Cns Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Cns Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Cns Pharmaceuticals Stock:
Check out the analysis of Cns Pharmaceuticals Correlation against competitors.
To learn how to invest in Cns Stock, please use our How to Invest in Cns Pharmaceuticals guide.
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Cns Stock analysis

When running Cns Pharmaceuticals' price analysis, check to measure Cns Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cns Pharmaceuticals is operating at the current time. Most of Cns Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cns Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cns Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cns Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Money Managers
Screen money managers from public funds and ETFs managed around the world
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Is Cns Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cns Pharmaceuticals. If investors know Cns will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cns Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(7.60)
Return On Assets
(1.95)
Return On Equity
(5.60)
The market value of Cns Pharmaceuticals is measured differently than its book value, which is the value of Cns that is recorded on the company's balance sheet. Investors also form their own opinion of Cns Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Cns Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cns Pharmaceuticals' market value can be influenced by many factors that don't directly affect Cns Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cns Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cns Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cns Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.